Edition:
United Kingdom

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

7.30USD
24 Apr 2018
Change (% chg)

-- (--)
Prev Close
$7.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
46,832
52-wk High
$11.15
52-wk Low
$4.90

Latest Key Developments (Source: Significant Developments)

Minerva Neurosciences Announces Enrollment Of First Patient In Phase 2B Trial Comparing Seltorexant Versus Quetiapine
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2B TRIAL COMPARING SELTOREXANT (MIN-202) VERSUS QUETIAPINE AS ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER.  Full Article

Minerva Neurosciences Screens First Patient In Phase 3 Trial Of Schizophrenia Drug
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA.  Full Article

Minerva Neurosciences Screens First Patient In Phase 3 Trial Of MIN-101 To Treat Negative Symptoms In Schizophrenia
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA.MINERVA NEUROSCIENCES INC - ‍ TOP-LINE RESULTS FROM 12-WEEK DOUBLE BLIND PHASE OF TRIAL OF MIN-101 ARE EXPECTED IN FIRST HALF OF 2019​.  Full Article

Minerva Neurosciences names Richard Russell president
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES NAMES RICHARD RUSSELL PRESIDENT.MINERVA NEUROSCIENCES INC - REMY LUTHRINGER WILL CONTINUE AS CHIEF EXECUTIVE OFFICER OF MINERVA WHILE RESIGNING HIS POSITION AS PRESIDENT.  Full Article

Minerva Neurosciences reports Q3 loss per share $0.28
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Minerva Neurosciences Inc :Minerva Neurosciences Inc reports third quarter 2017 financial results and business updates.Q3 loss per share $0.28.Q3 earnings per share view $-0.00 -- Thomson Reuters I/B/E/S.Minerva Neurosciences Inc - ‍expects cash, cash equivalents and marketable securities will be sufficient to fund operations for at least next 12 months​.Minerva Neurosciences Inc - ‍cash, cash equivalents, marketable securities as of Sept 30, were about $143.3 million, compared to $83.0 million as of Dec 31, 2016​.  Full Article

Minerva Neurosciences Q3 loss per share $0.24
Thursday, 3 Nov 2016 

Minerva Neurosciences Inc : Minerva Neurosciences - intend to meet with FDA to determine late stage clinical strategy, specifically design of next clinical trials with MIN-101 . Minerva Neurosciences Inc - objective is to initiate trials for min-101 in mid-2017 . Minerva neurosciences reports third quarter 2016 financial results and business updates .Q3 loss per share $0.24.  Full Article

Minerva Neurosciences reports quarterly loss per share $0.18
Thursday, 4 Aug 2016 

Minerva Neurosciences Inc : Quarterly loss per share of $0.18 .Expects that its cash, cash equivalents and marketable securities on hand at June 30, 2016 will be sufficient to fund its operations into 2018.  Full Article

Minerva Neurosciences prices of public offering of common stock
Tuesday, 14 Jun 2016 

Minerva Neurosciences Inc :Minerva Neurosciences announces pricing of public offering of common stock.  Full Article

Minerva Neurosciences announces proposed public offering of common stock
Monday, 13 Jun 2016 

Minerva Neurosciences Inc : Minerva Neurosciences announces proposed public offering of common stock .Intends to use net proceeds to fund part of continued clinical development of Min-101, Min-117, Min-202 and Min-301.  Full Article

Minerva neurosciences announces proposed public offering of common stock
Monday, 13 Jun 2016 

Minerva Neurosciences Inc : Minerva neurosciences announces proposed public offering of common stock .Intends to use net proceeds from offering, to fund part of continued clinical development of MIN-101, MIN-117, MIN-202 and MIN-301.  Full Article

BRIEF-Minerva Neurosciences Screens First Patient In Phase 2B Trial Of Min 117 To Treat Major Depressive Disorder

* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 2B TRIAL OF MIN 117 TO TREAT MAJOR DEPRESSIVE DISORDER